cancer Clinical Trials

Phase I Clinical Trial Shows Some Promise for Investigational Drug for Melanoma

An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center and other institutions have reported. In JCI Insight, UNC Lineberger’s Stergios Moschos, MD, and colleagues published the results […]

Biotechnology

Beta Blockers May Boost Immunotherapy, Help Melanoma Patients Live Longer

A common, inexpensive drug that is used to prevent heart attacks and lower blood pressure may also help melanoma patients live longer. Researchers at Penn State found that melanoma patients who received immunotherapy while taking a specific type of beta blocker lived longer than patients who received immunotherapy alone. In a follow-up experiment with mice, […]

Biotechnology Uncategorized

Topical gel made from oral blood pressure drugs shown effective in healing chronic wounds

An international team of researchers led by Johns Hopkins has shown that a topical gel made from a class of common blood pressure pills that block inflammation pathways speeds the healing of chronic skin wounds in mice and pigs. A report of the findings, published Oct. 16 in the Journal of Investigative Dermatology, marks efforts […]

Biotechnology

New Treatment Shows Promise for Patients with Rare Dermatologic Disease

A new treatment for a rare and often incurable condition called dermatomyositis (DM) reduced the severity of the disease in patients whose DM was resistant to other therapies. As part of a randomized, double-blind study conducted at the Perelman School of Medicine at the University of Pennsylvania, 22 patients were given either a drug called anabasum […]

Biotechnology cancer Clinical Trials Immunotherapies

Study Unlocks How Changes in Gene Activity Early During Therapy Can Establish the Roots of Drug-Resistant Melanoma

FINDINGS A UCLA-led study of changes in gene activity in BRAF-mutated melanoma suggests these epigenomic alterations are not random but can explain how tumors are already developing resistance as they shrink in response to treatment with a powerful class of drugs called MAP kinase (MAPK)-targeted inhibitors. The discovery marks a potential milestone in the understanding […]

Dermatology Gene Therapy

Autologous Cell Therapy for Epidermolysis Bullosa Gains FDA Breakthrough Therapy Designation

Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation status to the Company’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB).  The designation from the FDA enables collaborative […]

Antibiotics Biotechnology rare diseases

Penn study details impact of antibiotics, antiseptics on skin microbiomes

The use of topical antibiotics can dramatically alter communities of bacteria that live on the skin, while the use of antiseptics has a much smaller, less durable impact. The study, conducted in mice in the laboratory of Elizabeth Grice, PhD, an assistant professor of Dermatology in the Perelman School of Medicine at the University of […]

Biotechnology cancer Dermatology rare diseases

Cancer therapy shows promise for psoriasis treatment

HDAC inhibitors, already widely used to treat cancer, may be an effective therapy for psoriasis as well, scientists report. They have shown that HDAC3 inhibitors are particularly adept at increasing expression of aquaporin-3, or AQP3, a channel that transports glycerin, a natural alcohol and water attractor, which helps skin look better and aids healthy production […]

cancer

Drug Combination Delivered by Nanoparticles May Help in Melanoma Treatment

The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers. CelePlum-777 combines a special ratio of the drugs Celecoxib, an anti-inflammatory, and Plumbagin, a toxin. By combining the drugs, the cells have difficulty […]

Biotechnology Dermatology

Penn Medicine Launches First Apple ResearchKit App for Sarcoidosis Patients

App combines patient resources with research Penn Medicine today launched its first Apple ResearchKit app, focused on patients with sarcoidosis, an inflammatory condition that can affect the lungs, skin, eyes, heart, brain, and other organs. The effort marks Penn’s first time using modules from Apple’s ResearchKit framework, as part of the institution’s focus on mobile […]

Dermatology Gene Therapy

Gene therapy for blistering skin disease appears to enhance healing in clinical trial

Grafting sheets of a patient’s genetically corrected skin to open wounds caused by the blistering skin disease epidermolysis bullosa appears to be well-tolerated and improves wound healing, according to a phase-1 clinical trial conducted by researchers at the Stanford University School of Medicine. The results mark the first time that skin-based gene therapy has been […]